Regent Assay advises CellPath on its sale to StatLab

CellPath has announced its sale to StatLab, a portfolio business of Audax Private Equity and Linden Capital Partners, which is a prominent developer and manufacturer of medical diagnostic supplies and equipment. With the acquisition of CellPath Ltd., StatLab expands its global reach and key production capabilities while gaining an established UK customer base and positioning it for international growth and market expansion.

CellPath was founded by Peter Webber in 1969 as a histology consumables company, eventually expanding into equipment and today is a company that specialises in the manufacture and global supply of cellular pathology products, consumables, and services. The CellPath brand is connected with cutting-edge, well-proven solutions that are made to a high quality.  CellPath products support the cellular pathology workflow of leading hospitals and laboratories in the United Kingdom and Europe.

StatLab is a portfolio company of Audax Private Equity and Linden Capital Partners. They teamed up with StatLab in 2020 to launch a global instrumentation and consumable goods business in the life science instruments and diagnostics industries. StatLab Medical Products is a US-based market leader in the development and production of high-quality histology, cytology, and immunohistochemistry diagnostics. It partners with anatomic pathology laboratories to provide convenient access to more than 3,500 high-quality diagnostic equipment at affordable prices, all backed by expert support.

The addition of CellPath to the StatLab family broadens the combined company’s manufacturing capabilities and product portfolio and, in concert with the prior Pyramid acquisition, serves as StatLab’s European beachhead, helping to accelerate international organic growth.

The Regent Assay team is pleased to have worked with the CellPath team in achieving this milestone.

This transaction demonstrates Regent Assay’s continued expertise and track record in the healthcare sector.